Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Calcium Carbonate→

Calcium Carbonate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
471-34-1
Molecular formula
CCaO3
Molecular weight
100.09 g/mol
Drug class
Inorganic calcium saltcalcium supplement, antacid and phosphate-binding agent
Mechanism of action
Dissociates in the gastrointestinal tract to provide calcium ions. Calcium carbonate neutralises gastric hydrochloric acid and, in the intestine, binds phosphate to form poorly absorbed calcium-phosphate complexes; the product formulation and administration with food determine its use.
Indications / reported uses
  • Calcium supplementation and prevention or treatment of inadequate calcium intake
  • Symptomatic relief of acid-related dyspepsia and heartburn in authorised antacid formulations
  • Phosphate binding in selected patients with chronic kidney disease where specifically authorised; monitor calcium and phosphate balance

Sources: US DailyMed — Calcium carbonate products · NIH Office of Dietary Supplements — Calcium fact sheet · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Inorganic calcium salt; calcium supplement, antacid and phosphate-binding agent

Mechanism of action

Dissociates in the gastrointestinal tract to provide calcium ions. Calcium carbonate neutralises gastric hydrochloric acid and, in the intestine, binds phosphate to form poorly absorbed calcium-phosphate complexes; the product formulation and administration with food determine its use.

General use cases

  • Calcium supplementation and prevention or treatment of inadequate calcium intake
  • Symptomatic relief of acid-related dyspepsia and heartburn in authorised antacid formulations
  • Phosphate binding in selected patients with chronic kidney disease where specifically authorised; monitor calcium and phosphate balance

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Calcium Carbonate Environmental Risk Assessment (ERA) (the Calcium Carbonate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.